Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
“A novel virus, a novel treatment
Infection with SARS-CoV-2 induces a unique inflammatory response in which the IFN-I-mediated antiviral component is much lower than the pro-inflammatory component, which likely contributes to the life-threatening “cytokine storms” that afflict patients with severe disease. Preferentially increasing the IFN-I response has the potential to correct this imbalance.
In studies with human lung epithelial cells, our isRNAs increased the IFN-I pathway without increasing inflammation, resulting in >95% inhibition of influenza infection and >99% inhibition of SARS-CoV-2 infection. The isRNAs also inhibited SARS-CoV-2 infection in vivo in a hamster COVID-19 model. This technology could be used both to prevent infection as well to treat patients after they contract COVID-19 and other viral diseases, and may be particularly useful when administered via inhalation or intranasally.“
https://wyss.harvard.edu/technology/broad-spectrum-rna-therapeutic-for-covid-19-and-influenza/
“ As part of its strategy to attack our bodies, the coronavirus appears to tamp down interferon. That finding has encouraged researchers to see whether a boost of interferon might help people weather Covid-19, particularly early in infection. Early studies, including experiments in cells and mice, have yielded encouraging results that have led to clinical trials.
An open-label study in China suggested that the molecules could help prevent healthy people from getting infected. “
https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html
About John Holloway:
John Holloway together with Professor Stephen Holgate continued his research into the genetic basis of allergies and asthma.
Event from Uni of Southampton:
Date And Time:
Tue, February 9, 2021
6:00 PM – 7:00 PM GMT
Location ;
Online Event
Hosted by Professor John Holloway, Professor of Allergy and Respiratory Genetics and also Associate Dean (Research) in the Faculty of Medicine at the University this insightful discussion will be followed by a live Q&A session.
https://www.eventbrite.co.uk/e/beating-covid-19-trials-vaccinations-prevention-tickets-131896250235
Thanks Trek
Looks like we both are on same page.
If you look at my previous posts I only post the content I research and only with supporting evidence. I am man of few words and this might be my biggest message.
To be honest I recently got fed up with this board and attempted to follow the advise of a fellow poster to move on to other domains, where I had registered newly and seems some coins are required to be onboard.
That’s when I decided to stick with the masses than the elite and realised my mistake.
Anyway, to let you know I had got the journals reviewed by a scholar in biotechnology who had won accolades and is one of the BOD for one of the European countries and all I can tell you is, she had given a THUMPS UP. :-)
Again, SIT BACK RELAX AND NJOI THE SHOW...
For LTH’s, I believe you had all done your research and I think we had reached a point where we can can turn off the RESEARCH mode. That’s where I am...
SIT BACK RELAX AND NJOI THE SHOW... :-)
“
? A therapy to prevent severe viral disease could provide a stopgap measure to offset the dire need for vaccines in the current pandemic, and it would dramatically change the calculus of how society responds to future emerging viral threats. ”
https://www.universitynewshq.com/university-news/severe-covid-19-disables-disease-fighting-immune-circuit/
“ The FDA has authorized only two therapeutics to treat Covid-19. But, the monoclonal antibody ****tails, developed by Eli Lilly and Regeneron, are not being given to many patients. In December, it was estimated that 80% of all doses were still sitting on shelves…unopened. ”
https://detroit.cbslocal.com/2021/01/21/daily-covid-19-minute-how-to-get-monoclonal-antibody-therapy/
“Amazon to open pop-up COVID-19 vaccine clinic in Seattle headquarters”
https://www.reuters.com/article/us-health-coronavirus-amazon-com-vaccine-idUSKBN29R0D8
This to me is assurance that SNG primary endpoint is walk in the park.
SNG RNS extract:
“ The primary endpoints are now ‘time to hospital discharge’ and ‘time to recovery’. The primary assessment of efficacy will be supported by the key secondary endpoint of ‘progression to severe disease or death’ and other secondary endpoints. Both primary endpoints have at least 90% power to detect a statistically significant effect of SNG001 compared to placebo”
“ Guillen Nieto pointed out that with its application more than 60 percent of the patients had a negative PCR test after seven or nine days of stay in the hospitals, instead of the 15 days previously registered.”
https://www.cubasi.cu/en/news/cuban-biotechnology-progresses-tackling-covid-19-pandemic
Eric Topol with 470k followers tagging Uni Of Southampton
https://twitter.com/erictopol/status/1348675207444135938?s=21
COPD is forecast to be the third leading cause of death worldwide (after heart attack and stroke) by 2030
12 million adults in the USA have reported a physician diagnosis of COPD. However, as many as 24 million adults have some evidence of impaired lung function, implying an under-diagnosis of this disease
The economic cost to the USA of COPD is $42.6 billion per year
Hospital care cost $11.3 billion2 and in 2005 there were 721,000 hospitalizations for COPD in the USA
https://www.ipgroupplc.com/media/portfolio-news/2009/2009-09-04b
These are only 2009 stats
To put it simple analogy:
If we compare Vaccines to Apple iOS, and to respond to mutations, Apple needs to research, develop and continuously release patches to keep apple devices free from viruses.
On the other-hand for SNG001, once regulatory approval is done, that’s it. No further patches needed to keep the virus away.
Today SNG might look behind vaccines but once approved this will be way ahead of vaccines.
Reading the news on new treatments, it’s good to hear these are saving lives.
From my understanding, once SNG001 is approved and available for treatment, from then on, only anything that slips the Synairgen’s net is available to these new treatments.
Correct me if I am wrong.
When audience were cheering Whoo Hoo .. sounded to me Boo Hoo.. lol
https://youtu.be/gVgI6hC5iOY
"We don't want to sit in an island in the world where rich countries are fully immunized, while the rest of the world is dying from COVID," he says. "That's just not a morally convenient place to be for most people."
About 7 billion people live on the planet. Many of the new COVID-19 vaccines require two doses. So to stamp out the pandemic, companies need to manufacture about 12 to 15 billion doses.
Problem is, right now, the world doesn't have near that many doses and likely won't have them this year, Lusiani says. "In many pockets around the world, it's becoming increasingly likely that people will not get access to the COVID-19 vaccine in 2021."
Many families will have to wait until 2023 or 2024. And the pandemic will likely continue until then.
So why can't the world simply manufacture more doses? Lawyer Brook Baker at Northeastern University believes there's an underlying root cause: international patents on COVID-19 vaccines.
"The [vaccine] innovators hold patent rights and trade secret rights over those technologies, and they're unwilling to share them broadly to other manufacturers. So we have artificially constricted supply," says Baker, who studies how laws affect access to medicines.
The patent rights come from agreements within the World Trade Organization. Members of the WTO, which includes 159 countries, have agreed to honor patents for new pharmaceutical products at least 20 years after they're developed.
"This agreement was the brainchild of the pharmaceutical industry back in the 1980s," Baker says. "It ended up being a monopoly-based agreement, which preserves the rights of the pharmaceutical industry instead of allowing competition."
https://www.gpb.org/news/goats-and-soda/2021/01/05/what-will-it-take-end-the-covid-19-pandemic
“ Synairgen PLC (LON: SNG)- It is a company engaged in the development of the respiratory drug, established in 2003.
Market Capitalization
£289.88 million
1 year return
2,382.8 per cent
YTD return
2,368.09 per cent
Synairgen made significant clinical progress with SNG001 during H1 2020 ending 30 June. The phase II trial of its inhaled formulation of interferon beta, SNG001, indicated that it is a valuable option for the treatment of Covid-19 patients. The net assets of the company were recorded at £11.58 million as compared to £4.30 million on 30 June 2019. Synairgen was successful in raising £14.0 million (before expenses) in an equity issue to be utilised for Covid-19 related activities.
With complete focus on accelerating the discussions with regulatory authorities for approval regarding SNG001, the company aims at delivering effective treatment for Covid-19 and is working in favour of patients and its shareholders.”
https://kalkinemedia.com/uk/stocks/healthcare/whats-in-store-for-healthcare-stocks-in-2021-top-5-picks
These are stats from 2009:
“ Asthma statistics
There are approximately 23 million asthmatics in the USA
The economic cost to the USA of asthma is $19.7 billion per year
Asthma accounts for 1.7 million emergency department visits per year in the USA
The cost of emergency department visits and in-patient care in relation to asthma in the USA is $4.7 billion
The average duration of a hospitalisation for an asthma exacerbation in the USA is 2.7 days at a cost of $9,0784
50% of the total cost of the asthma is apportioned to 10% of the asthmatic population with the severest disease
COPD statistics:
COPD includes chronic bronchitis and emphysema
COPD is forecast to be the third leading cause of death worldwide (after heart attack and stroke) by 2030
12 million adults in the USA have reported a physician diagnosis of COPD. However, as many as 24 million adults have some evidence of impaired lung function, implying an under-diagnosis of this disease
The economic cost to the USA of COPD is $42.6 billion per year
Hospital care cost $11.3 billion2 and in 2005 there were 721,000 hospitalizations for COPD in the USA
Rhinovirus (common cold virus) and exacerbations (worsening of symptoms) of asthma and COPD
Adults get an average of two to four colds per year, mostly between September and May. Young children suffer from an average of six to eight colds per year
Rhinovirus infections are the major cause of asthma exacerbations, accounting for 50% to 80% of all such attacks in both children and adults
80-85% of COPD exacerbations are associated with viral or bacterial respiratory tract infections with rhinovirus and Haemophilus influenzae thought to be the major contributors”
https://www.ipgroupplc.com/media/portfolio-news/2009/2009-09-04b
Happy New Year all!
Stay Safe!